Genmab — Maj 2019

[bibob]

Poseida Therapeutics Reseives US FDA Orphan Drug designation for P-BCMA 101 for the treatment of MM https://m.firstwordpharma.com/poseida-therapeutics-receives-us-fda-orphan-drug-designation-p-bcma-101-treatment-multiple-myeloma

[StockBull]

Interessandt at se Vanguard og Artisan har øget til 26.49%, en stigning på 1.63% i år. Samme periode er Blackrock reduceret med 0.98%. Trenden er således stadig at top 20 øger deres Genmab investering og nu har 51.12% af aktierne.

[Helge_LarsenPI-redaktør]

Just a moment...

(www.proinvestor.com)

[Bulder]

Er der nogen der har et klokkeslet for offentliggørelsen af asco-abstr i morgen?

[E_L]

evening US, so I expect your summary on thursday morning

[Bulder]

[JohnW]

Zymeworks: https://finance.yahoo.com/news/zymeworks-enters-first-zymelink-antibody-104500488.html

[Schiff]

Synes ikke der er meget RTOR over den MAIA ansøgning. Jeg ved ikke om jeg forstår den her tegning https://www.fda.gov/about-fda/oncology-center-excellence/real-time-oncology-review-pilot-program men kan det passe at Janssen completed sBLA submission den 12. marts? https://johnsonandjohnson.gcs-web.com/static-files/5cec96a8-449f-4608-8890-a83c0b00d0b9 Herfra går der ifølge FDA ca. 4 uger? nu er der så gået 8 uger.

[Solsen]

Det tror jeg vi er mange der spørger om. Men mon ikke vi er tæt på jf Genmab (JW, Andrew)

[Bulder]

Winkel fra CC om RTOR og Maia: It's up to the gods at the FDA right now, but I think the process is going well, and there is no reason to be concerned at all. It's an experimental program. It's a pilot program. So the time lines are not fixed, but we expect it very, very shortly.

[JKY_VH]

har der ikke været nævnt 20.5 her i debatten?

[royal]

Jeg smider et par flasker god hvidvin i køleskabet. De overlever ikke til lørdag morgen. (Uanset hvad )

[royal]

De fleste af os forventede at RTOR var lig med meget hurtig behandlingstid. Vi er nu meget klogere.

[KWC]

Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement

Copenhagen, Denmark; May 14, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 9,737 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

3,000 shares at DKK 40.41,
5,000 s

[KWC]

Proceeds to the company are approximately DKK 1.61 million. The increase corresponds to approx. 0.02% of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2019. The new shares will be listed on Nasdaq Copenhagen after registration with th

[KWC]

with the Danish Business Authority. The capital increase is expected to be finalized shortly.

[KWC]

3,000 shares at DKK 40.41,
5,000 shares at DKK 174.00,
188 shares at DKK 225.90,
500 shares at DKK 231.50,
187 shares at DKK 337.40, and
862 shares at DKK 466.20.

[Plimsoller]

God morgen

[polle1]

God morgen og god dag

[Helge_LarsenPI-redaktør]

God morgen.